Regeneron Pharmaceuticals Inc
REGNHealthcare|Biotechnology|USA
$763.04
+1.19 (+0.16%)
DCF (FCF)
$641.30
Tangible Book
$283.77
Graham Number
$532.32
Earnings Power
$496.16
About
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Stock Price
+25.0%(1Y)
Pipeline Summary
506 total trials133
Phase 1
161
Phase 2
115
Phase 3
56
Phase 4
Active: 38Terminated: 40Completed: 284Recruiting: 89NOT_YET_RECRUITING: 15AVAILABLE: 2Unknown: 11NO_LONGER_AVAILABLE: 3Withdrawn: 16SUSPENDED: 1ENROLLING_BY_INVITATION: 3APPROVED_FOR_MARKETING: 3TEMPORARILY_NOT_AVAILABLE: 1
Active Trials (127)
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771Asthma
Phase 2Active
Enrollment: 240 participants
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma
Phase 2Active
Enrollment: 231 participants
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144Solid Tumor, Adult
Phase 1Phase 2Active
Enrollment: 98 participants
Transformative Research in Diabetic Nephropathy 2.0
NCT07444203Diabetic Nephropathies
Recruiting
Enrollment: 200 participants
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105Melanoma
Phase 2Recruiting
Enrollment: 87 participants
BioScore
7.8/10
Buy
Ownership
Recent Insider Trades
RYAN ARTHUR FSELL
2026-04-01100 shares @ $777.27
RYAN ARTHUR FSELL
2026-03-02100 shares @ $785.5
Zoghbi Huda YSELL
2026-02-191,638 shares @ $781.33
RYAN ARTHUR FSELL
2026-02-09100 shares @ $778.53
Pitofsky JasonSELL
2026-02-092,036 shares @ $778.52
Recent News
2026-04-03 22:01:11
2026-04-02 21:00:11
2026-04-02 21:00:08
2026-04-02 16:27:57
2026-04-02 16:00:04
Data last updated: Apr 7, 2026, 03:33 AM